By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

CVS’s expansion into primary care is expected to drive long-term growth, while Gilead’s strong pipeline and market position in virology and oncology support its continued dividend growth.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

CVS Health Corp., one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from ...

Importantly Deutsche Bank's PBM analyst George Hill said that CVS Caremark (NYSE: CVS) could be next in line to take a decision here. It could either follow Express Scripts or take Gilead's side.